Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RYAN T FISCHER

Allopathic & Osteopathic Physicians Pediatrics Pediatric Transplant Hepatology

NPI
1093981946
CMS profile
4822
Location
KANSAS CITY, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$57,796.57

78 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Mirum Pharmaceuticals, Inc. $42,749.16 66
Ipsen Biopharmaceuticals, Inc $14,923.45 10
Ipsen Pharma SAS $74.99 1
ALBIREO PHARMA, INC. $48.97 1

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RYAN T FISCHER

NPI 1093981946 · CMS profile ID 4822

Allopathic & Osteopathic Physicians / Pediatrics / Pediatric Transplant Hepatology

KANSAS CITY, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1093981946?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RYAN T FISCHER, NPI 1093981946, CMS profile ID 4822. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1093981946?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). RYAN T FISCHER, NPI 1093981946, CMS profile ID 4822. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1093981946?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
RYAN T FISCHER, NPI 1093981946, CMS profile ID 4822, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–78 of 78 matching records. This page contains 28 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1093981946?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

78 matching records · $57,796.57 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 78 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–78 of 78.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Mirum Pharmaceuticals, Inc. $88.9105/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324783 CMS
Mirum Pharmaceuticals, Inc. $2,762.5005/30/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324785 CMS
Ipsen Biopharmaceuticals, Inc $10.6304/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091969089 CMS
Ipsen Biopharmaceuticals, Inc $265.0003/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091969091 CMS
Ipsen Biopharmaceuticals, Inc $317.1003/28/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091969093 CMS
Ipsen Biopharmaceuticals, Inc $5,887.0003/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091969095 CMS
Ipsen Biopharmaceuticals, Inc $112.0603/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1091969097 CMS
Mirum Pharmaceuticals, Inc. $22.0002/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324725 CMS
Mirum Pharmaceuticals, Inc. $31.0002/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324727 CMS
Mirum Pharmaceuticals, Inc. $30.0002/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324729 CMS
Mirum Pharmaceuticals, Inc. $4.1702/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324731 CMS
Mirum Pharmaceuticals, Inc. $12.2502/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324733 CMS
Mirum Pharmaceuticals, Inc. $92.5502/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324735 CMS
Mirum Pharmaceuticals, Inc. $3,080.0002/12/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324737 CMS
Mirum Pharmaceuticals, Inc. $9.0602/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324739 CMS
Mirum Pharmaceuticals, Inc. $20.0002/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324741 CMS
Mirum Pharmaceuticals, Inc. $20.0002/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324743 CMS
Mirum Pharmaceuticals, Inc. $32.0302/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324745 CMS
Mirum Pharmaceuticals, Inc. $3,080.0002/06/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324747 CMS
Mirum Pharmaceuticals, Inc. $25.0002/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324749 CMS
Mirum Pharmaceuticals, Inc. $19.9602/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324751 CMS
Mirum Pharmaceuticals, Inc. $40.2002/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324753 CMS
Mirum Pharmaceuticals, Inc. $327.8802/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324755 CMS
Mirum Pharmaceuticals, Inc. $35.0002/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324757 CMS
Mirum Pharmaceuticals, Inc. $27.4602/06/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324759 CMS
Mirum Pharmaceuticals, Inc. $6.8402/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324761 CMS
Mirum Pharmaceuticals, Inc. $3,080.0002/06/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324763 CMS
Mirum Pharmaceuticals, Inc. $5.7902/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1123324765 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $112.28 7
PY2021 $28.54 1
PY2022 $25,262.65 29
PY2023 $68,466.36 48
PY2024 $57,796.57 78
PY2025 $427.96 10

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $137,786.56 57
PY2024 Principal investigator $193,743.73 44
PY2023 Principal investigator $117,430.81 40
PY2022 Principal investigator $164,501.56 59
PY2021 Principal investigator $4,887.00 8
PY2020 Principal investigator $8,148.00 14
PY2019 Principal investigator $2,197.00 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

57 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ALBIREO PHARMA, INC. $1,000.00 12/18/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy No dispute reported 06/30/2026 1176479267
Principal investigator 1 Gilead Sciences, Inc. $2,339.00 12/16/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide in Children Adolescents with Chronic Hepatitis B Infection No dispute reported 06/30/2026 1229213999
Principal investigator 1 Gilead Sciences, Inc. $264.00 12/16/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide in Children Adolescents with Chronic Hepatitis B Infection No dispute reported 06/30/2026 1229214009
Principal investigator 1 ALBIREO PHARMA, INC. $550.00 11/06/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy No dispute reported 06/30/2026 1176479263
Principal investigator 1 ALBIREO PHARMA, INC. $800.00 11/06/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) No dispute reported 06/30/2026 1176479265
Principal investigator 1 ALBIREO PHARMA, INC. $1,050.00 10/30/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy No dispute reported 06/30/2026 1176479253
Principal investigator 1 ALBIREO PHARMA, INC. $1,253.75 10/30/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176479261
Principal investigator 1 Gilead Sciences, Inc. $3,041.00 10/28/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide in Children Adolescents with Chronic Hepatitis B Infection No dispute reported 06/30/2026 1229213990
Principal investigator 1 Gilead Sciences, Inc. $3,041.00 10/21/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide in Children Adolescents with Chronic Hepatitis B Infection No dispute reported 06/30/2026 1229213978
Principal investigator 1 ALBIREO PHARMA, INC. $585.63 10/14/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176479255
Principal investigator 1 ALBIREO PHARMA, INC. $15,520.47 10/14/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176479259
Principal investigator 1 ALBIREO PHARMA, INC. $1,237.25 10/09/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176479257
Principal investigator 1 ALBIREO PHARMA, INC. $600.00 09/25/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy No dispute reported 06/30/2026 1176479245
Principal investigator 1 ALBIREO PHARMA, INC. $2,436.32 09/25/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) No dispute reported 06/30/2026 1176479251
Principal investigator 1 ALBIREO PHARMA, INC. $907.17 09/18/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) No dispute reported 06/30/2026 1176479249
Principal investigator 1 Gilead Sciences, Inc. $2,339.00 09/16/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide in Children Adolescents with Chronic Hepatitis B Infection No dispute reported 06/30/2026 1229213963
Principal investigator 1 ALBIREO PHARMA, INC. $3,356.81 09/11/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176479247
Principal investigator 1 Gilead Sciences, Inc. $1,200.00 08/26/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide in Children Adolescents with Chronic Hepatitis B Infection No dispute reported 06/30/2026 1229213952
Principal investigator 1 ALBIREO PHARMA, INC. $438.64 08/21/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy No dispute reported 06/30/2026 1176479241
Principal investigator 1 ALBIREO PHARMA, INC. $1,295.55 08/12/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) No dispute reported 06/30/2026 1176479243
Principal investigator 1 ALBIREO PHARMA, INC. $2,847.55 07/29/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) No dispute reported 06/30/2026 1176479237
Principal investigator 1 ALBIREO PHARMA, INC. $4,187.86 07/29/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) No dispute reported 06/30/2026 1176479239
Principal investigator 1 ALBIREO PHARMA, INC. $1,546.83 07/24/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176479233
Principal investigator 1 ALBIREO PHARMA, INC. $1,500.00 07/24/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) No dispute reported 06/30/2026 1176479235
Principal investigator 1 Gilead Sciences, Inc. $6,299.00 07/08/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide in Children Adolescents with Chronic Hepatitis B Infection No dispute reported 06/30/2026 1229213942
Principal investigator 1 ALBIREO PHARMA, INC. $1,050.00 06/25/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy No dispute reported 06/30/2026 1176479223
Principal investigator 1 ALBIREO PHARMA, INC. $4,187.86 06/25/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) No dispute reported 06/30/2026 1176479231
Principal investigator 1 ALBIREO PHARMA, INC. $1,950.00 06/24/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy No dispute reported 06/30/2026 1176479221
Principal investigator 1 ALBIREO PHARMA, INC. $4,140.00 06/24/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176479227
Principal investigator 1 ALBIREO PHARMA, INC. $1,576.83 06/19/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176479229
Principal investigator 1 Gilead Sciences, Inc. $2,137.00 06/17/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide in Children Adolescents with Chronic Hepatitis B Infection No dispute reported 06/30/2026 1229213933
Principal investigator 1 ALBIREO PHARMA, INC. $11,862.30 06/05/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176479225
Principal investigator 1 ALBIREO PHARMA, INC. $50.00 05/15/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy No dispute reported 06/30/2026 1176479215
Principal investigator 1 ALBIREO PHARMA, INC. $6,140.00 05/08/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) No dispute reported 06/30/2026 1176479217
Principal investigator 1 ALBIREO PHARMA, INC. $1,400.00 05/08/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) No dispute reported 06/30/2026 1176479219
Principal investigator 1 Gilead Sciences, Inc. $1,464.00 05/01/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide in Children Adolescents with Chronic Hepatitis B Infection No dispute reported 06/30/2026 1229213921
Principal investigator 1 ALBIREO PHARMA, INC. $4,327.50 04/24/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) No dispute reported 06/30/2026 1176479209
Principal investigator 1 ALBIREO PHARMA, INC. $2,530.36 04/24/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) No dispute reported 06/30/2026 1176479211
Principal investigator 1 Gilead Sciences, Inc. $1,519.00 04/22/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide in Children Adolescents with Chronic Hepatitis B Infection No dispute reported 06/30/2026 1229213911
Principal investigator 1 ALBIREO PHARMA, INC. $3,024.75 04/17/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176479207
Principal investigator 1 ALBIREO PHARMA, INC. $50.00 04/17/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) No dispute reported 06/30/2026 1176479213
Principal investigator 1 ALBIREO PHARMA, INC. $1,050.00 04/04/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy No dispute reported 06/30/2026 1176479203
Principal investigator 1 ALBIREO PHARMA, INC. $3,919.21 04/04/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176479205
Principal investigator 1 ALBIREO PHARMA, INC. $1,663.83 03/27/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176479199
Principal investigator 1 ALBIREO PHARMA, INC. $2,177.52 03/27/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) No dispute reported 06/30/2026 1176479201
Principal investigator 1 Gilead Sciences, Inc. $3,527.00 03/25/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide in Children Adolescents with Chronic Hepatitis B Infection No dispute reported 06/30/2026 1229213901
Principal investigator 1 Gilead Sciences, Inc. $2,137.00 03/18/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide in Children Adolescents with Chronic Hepatitis B Infection No dispute reported 06/30/2026 1229213889
Principal investigator 1 ALBIREO PHARMA, INC. $433.08 03/13/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176479197
Principal investigator 1 ALBIREO PHARMA, INC. $500.00 02/06/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy No dispute reported 06/30/2026 1176479193
Principal investigator 1 ALBIREO PHARMA, INC. $1,834.80 02/06/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) No dispute reported 06/30/2026 1176479195
Principal investigator 1 ALBIREO PHARMA, INC. $588.33 01/30/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176479187
Principal investigator 1 ALBIREO PHARMA, INC. $2,048.49 01/30/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevixibat (A4250) in Children with Biliary Atresia (BOLD-EXT) No dispute reported 06/30/2026 1176479191
Principal investigator 1 Gilead Sciences, Inc. $61.00 01/28/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide in Children Adolescents with Chronic Hepatitis B Infection No dispute reported 06/30/2026 1229213879
Principal investigator 1 ALBIREO PHARMA, INC. $3,614.87 01/23/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
An Open Label Study to Evaluate the Long-term Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT-EXT) No dispute reported 06/30/2026 1176479189
Principal investigator 1 Gilead Sciences, Inc. $2,339.00 01/22/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Phase 2/3 Randomized, Double-Blind Evaluation of the Pharmacokinetics, Safety, and Antiviral Efficacy of Tenofovir Alafenamide in Children Adolescents with Chronic Hepatitis B Infection No dispute reported 06/30/2026 1229213870
Principal investigator 1 ALBIREO PHARMA, INC. $2,746.00 01/16/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy No dispute reported 06/30/2026 1176479185
Principal investigator 1 ALBIREO PHARMA, INC. $2,100.00 01/03/2025 Covered Recipient Teaching Hospital
Childrens Mercy Hospital
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Odevixibat (A4250) in Children With Biliary Atresia Who Have Undergone a Kasai Hepatoportoenterostomy No dispute reported 06/30/2026 1176479183